摘要
目的观察多西他赛与培美曲塞在晚期非小细胞肺癌患者靶向治疗失败后的化疗效果。方法90例晚期非小细胞肺癌靶向治疗失败后患者,以便利抽样法分组方式分为A组和B组,各45例。A组使用培美曲塞进行化疗,B组使用多西他赛进行化疗。比较两组患者疾病控制率、近期疗效、不良反应发生情况及生存时间。结果A组疾病控制率60.00%、近期总有效率53.33%与B组的48.89%、40.00%比较,差异无统计学意义(P>0.05)。A组脱发、皮疹、恶心呕吐、腹泻、骨髓抑制及食欲不振发生率分别为13.33%、26.67%、44.44%、13.33%、48.89%、60.00%,均低于B组的40.00%、53.33%、77.78%、35.56%、80.00%、88.89%,差异具有统计学意义(P<0.05)。A组生存时间为(10.17±1.33)个月,与B组的(9.86±1.47)个月比较,差异无统计学意义(P>0.05)。结论培美曲塞与多西他赛在晚期非小细胞肺癌患者靶向治疗失败后的化疗效果显著,但培美曲塞不良反应更少,故临床应为患者优选安全性更高的培美曲塞。
Objective To observe the chemotherapy effect of pemetrexed and docetaxel after failure of targeted therapy for advanced non-small cell lung cancer.Methods A total of 90 patients with advanced nonsmall cell lung cancer after failure of targeted therapy were divided into group A and group B by convenience sampling method,with 45 cases in each group.Group A received chemotherapy with pemetrexed,and group B received chemotherapy with docetaxel.The disease control rate,short-term efficacy,occurrence of adverse reactions and survival time were compared between the two groups.Results The disease control rate of group A was 60.00%,and recent total efficiency was 53.33%,which was not statistically significant compared with 48.89%and 40.00%of group B(P>0.05).The incidence rates of hair loss,rash,nausea and vomiting,diarrhea,bone marrow suppression and loss of appetite in group A were 13.33%,26.67%,44.44%,13.33%,48.89%,and 60.00%,which were lower than 40.00%,53.33%,77.78%,35.56%,80.00%,and 88.89%in group B,and the differences were statistically significant(P<0.05).The survival time of group A was(10.17±1.33)months,which was not statistically significant compared with(9.86±1.47)months of group B(P>0.05).Conclusion Pemetrexed and docetaxel have significant chemotherapy effects in patients with advanced non-small cell lung cancer after failure of targeted therapy,but pemetrexed has fewer adverse reactions,so pemetrexed should be preferred for patients in clinical practice.
作者
蔡雨轩
CAI Yu-xuan(Department of Thoracic Surgery,Donggang Central Hospital,Dandong 118300,China)
出处
《中国现代药物应用》
2022年第6期106-108,共3页
Chinese Journal of Modern Drug Application
关键词
培美曲塞
多西他赛
晚期非小细胞肺癌
靶向治疗失败
化疗
Pemetrexed
Docetaxel
Advanced non-small cell lung cancer
Failure of targeted therapy
Chemotherapy
